Yahoo
    NasdaqGS - Delayed Quote USD

    Humacyte, Inc. (HUMAW)

    0.0009 -0.0032 (-78.05%)
    At close: August 25 at 3:59:50 PM EDT
    Loading Chart for HUMAW
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

    Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
    Zacks 2d ago
    Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

    Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
    Zacks 3mo ago
    Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

    Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
    Zacks 3mo ago
    Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

    Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
    Zacks 6mo ago
    Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

    Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
    GlobeNewswire 4d ago
    Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

    Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
    GlobeNewswire 9d ago
    Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

    Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
    Zacks 11d ago
    Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

    Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
    Zacks 13d ago
    Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

    Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
    GlobeNewswire 17d ago
    Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

    Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
    Zacks 19d ago
    Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

    Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
    GlobeNewswire 20d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: